Role of noradrenergic functions in the modification of naloxone-precipitated withdrawal jumping in morphine-dependent mice by diabetes.
The role of noradrenergic functions in the modulation of naloxone-precipitated withdrawal jumping in morphine-dependent mice by diabetes were examined. Both diabetic and non-diabetic mice were chronically treated with morphine (8 - 45 mg/kg, s.c.) for 5 days. During this treatment, neither diabetic nor non-diabetic mice showed any signs of toxicity. After morphine treatment, withdrawal was precipitated by injection of naloxone (0.3 mg/kg, s.c.). The number of naloxone-precipitated withdrawal jumps within 5 min after injection of naloxone was significantly less in morphine-dependent diabetic mice than in morphine-dependent non-diabetic mice. However, there was no significant difference in the number of naloxone-precipitated withdrawal jumps from 5 to 15 min after injection of naloxone between diabetic and non-diabetic mice. The turnover rate of noradrenaline in the frontal cortex in morphine-dependent non-diabetic mice, but not in morphine-dependent diabetic mice, was significantly increased 5 min after administration of naloxone. These results suggest that the functional changes in central noradrenergic systems may be involved in the reduction of naloxone-precipitated jumping in morphine-dependent diabetic mice.
Kamei
J
J
Department of Pathophysiology and Therapeutics, Faculty of Pharmaceutical Science, Hoshi University, Tokyo, Japan.
Ohsawa
M
M
D000701:Analgesics, Opioid / Q000009:adverse effects; D000818:Animals; D002851:Chromatography, High Pressure Liquid; D003921:Diabetes Mellitus, Experimental / Q000209:etiology / Q000378:metabolism* / Q000503:physiopathology; D005625:Frontal Lobe / Q000378:metabolism; D008297:Male; D008734:Methoxyhydroxyphenylglycol / Q000378:metabolism; D051379:Mice; D008813:Mice, Inbred ICR; D009020:Morphine / Q000009:adverse effects; D009021:Morphine Dependence / Q000209:etiology / Q000378:metabolism* / Q000503:physiopathology; D009043:Motor Activity / Q000502:physiology*; D009270:Naloxone / Q000494:pharmacology*; D009292:Narcotic Antagonists / Q000494:pharmacology*; D009638:Norepinephrine / Q000378:metabolism*; D011941:Receptors, Adrenergic / Q000502:physiology; D013375:Substance Withdrawal Syndrome / Q000209:etiology / Q000378:metabolism* / Q000503:physiopathology
D000701:Analgesics, Opioid; D009292:Narcotic Antagonists; D011941:Receptors, Adrenergic; D009270:Naloxone; D008734:Methoxyhydroxyphenylglycol; D009020:Morphine; D009638:Norepinephrine